ADC Therapeutics SA (NYSE: ADCT) reported that its Phase 3 LOTIS-5 trial of ZYNLONTA in combination with rituximab met its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE